NNVC Share Price | NanoViricides, Inc. Stock Analysis & Recommendation

Q: How big is NanoViricides, Inc.?

As of Jun 18, NanoViricides, Inc. has a market capitalization of 21.54 million, categorizing it as a Micro Cap company.As of Jun 24, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -9.74 million.As of Jun 24, the reporting period shows Shareholder's Funds at 11.46 million and Total Assets at 12.82 million.

Q: What does NanoViricides, Inc. do?

Overview:NanoViricides, Inc. is a nano-biopharmaceutical research and development company engaged in the discovery, development, and commercialization of drugs to combat viral infections, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot:- Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)- Market-cap: USD 21.54 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -0.29- Return on Equity: -110.12%- Price to Book: 2.44Contact Details:- Address: 1 Controls Dr, SHELTON CT: 06484-6153- Tel: 1 203 9376137- Fax: 1 203 8595095- Website: http://www.nanoviricides.com/

Q: Is NanoViricides, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for NanoViricides, Inc. has changed from sideways to mildly bullish. However, the overall stance remains mixed, with the weekly MACD and RSI indicating bearish signals, while the monthly MACD shows a mildly bullish trend. The daily moving averages are mildly bullish, suggesting short-term strength. Despite this, the stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -14.46% compared to the S&P 500's 17.14%. Overall, the technical stance is mildly bullish but with significant caution due to bearish indicators in the weekly timeframe.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

165.71 k

Shareholding (Dec 2025)

FII

1.21%

Held by 11 FIIs

DII

95.38%

Held by 4 DIIs

Promoter

0.02%

How big is NanoViricides, Inc.?

22-Jun-2025

As of Jun 24, NanoViricides, Inc. has a market capitalization of 21.54 million, with net sales of 0.00 million and a net profit of -9.74 million over the latest four quarters. Shareholder's funds are 11.46 million and total assets are 12.82 million.

View full answer

What does NanoViricides, Inc. do?

22-Jun-2025

NanoViricides, Inc. is a nano-biopharmaceutical company focused on developing drugs for viral infections, with a market cap of $21.54 million and a recent net profit of -$2 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.

View full answer

Who are in the management team of NanoViricides, Inc.?

22-Jun-2025

As of March 2022, the management team of NanoViricides, Inc. includes Dr. Anil Diwan as Executive Chairman and President, along with independent directors Mr. Stanley Glick, Mr. Makarand Jawadekar, Mr. Theodore Rokita, and Mr. Brian Zucker.

View full answer

Is NanoViricides, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, NanoViricides, Inc. shows a mildly bullish trend in the short term, but caution is advised due to mixed signals from weekly indicators and underperformance compared to the S&P 500.

View full answer

Compare NanoViricides, Inc. with Similar Stocks

Virios Therapeutics, Inc.Lisata Therapeutics, Inc.Hepion Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 25 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.47

Return on Equity

-75.13%

Price to Book

2.22

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-20.17%

6 Months

-33.1%

1 Year

-28.57%

2 Years

-16.67%

3 Years

-23.39%

4 Years

-58.7%

5 Years

-79.35%

NanoViricides, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

1.20%

EBIT to Interest (avg)

-8.74

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.29

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

16.26%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.22

EV to EBIT

-2.32

EV to EBITDA

-2.50

EV to Capital Employed

3.29

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-141.77%

ROE (Latest)

-75.13%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (3.39%)

Foreign Institutions

Held by 11 Foreign Institutions (1.21%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -10.00% vs 4.76% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "-1.90",
          "chgp": "-10.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-2.00",
          "chgp": "-10.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is -14.46% vs 3.49% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.80",
          "val2": "-7.80",
          "chgp": "-12.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.50",
          "val2": "-8.30",
          "chgp": "-14.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.10

-1.90

-10.53%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.20

-2.00

-10.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -10.00% vs 4.76% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'25

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-8.80

-7.80

-12.82%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-9.50

-8.30

-14.46%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in year ended Jun 2025 is -14.46% vs 3.49% in Jun 2024

All Annual Results

Company CV

About NanoViricides, Inc.

NanoViricides, Inc.

Pharmaceuticals & Biotechnology

NanoViricides, Inc. is a nano-biopharmaceutical research and development company. The Company is engaged the discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company provides nanoviricide technology, which enables direct attacks at multiple points on a virus particle. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection. The nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company’s lead product candidate is NV-HHV-101 in the HerpeCide program, as a skin cream for the treatment of shingles rash.

Company Coordinates

Company Details

1 Controls Dr , SHELTON CT : 06484-6153

Tel: 1 203 9376137

http://www.nanoviricides.com/

Registrar Details